Unternehmensportrait
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Vorstand & Aufsichtsrat
| Vorstandsvorsitzender |
| Dr. Osamu Okuda |
| Vorstand |
| Toshiaki Itagaki |
| Aufsichtsrat |
| Dr. Osamu Okuda, Dr. Hisafumi Yamada, Toshiaki Itagaki, Dr. Mariko Y Momoi, Dr. Fumio Tateishi, Hideo Teramoto, Dr. Christoph Franz, Dr. James H. Sabry, Teresa A. Graham |
Unternehmensinformationen
| Name: |
Chugai Pharmaceutical Co., Ltd. |
| Adresse: |
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku,Tokyo 103-8324 |
| Telefon: |
+81-(0)3-3281-6611 |
| Fax: |
+81-(0)3-3281-6607 |
| E-Mail: |
-
|
| Internet: |
https://www.chugai-pharm.co.jp/english/index.html |
| Industrie: |
Gesundheitswesen |
| Sektor: |
Pharmazeutische Industrie |
| Sub-Sektor: |
- |
| Ende des Finanzjahres: |
31.12 |
| Streubesitz: |
- |
| IPO Datum: |
- |
Investor Relations
| Name: |
- |
| IR Telefon: |
+81-(0)3-3273-0554 |
| IR Fax: |
+81-(0)3-3281-6607 |
| IR E-Mail: |
-
|
